Clinical Trials List
2023-05-10 - 2025-04-30
Phase II
Terminated4
ICD-10C40.80
Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb
ICD-10C40.81
Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb
ICD-10C40.82
Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb
ICD-10C40.90
Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb
ICD-10C40.91
Malignant neoplasm of unspecified bones and articular cartilage of right limb
ICD-10C40.92
Malignant neoplasm of unspecified bones and articular cartilage of left limb
ICD-10C41.9
Malignant neoplasm of bone and articular cartilage, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9170.9
Malignant neoplasm of bone and articular cartilage, site unspecified
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Wen-Chi Shen Division of Hematology & Oncology
- 黃文冠 Division of Hematology & Oncology
- 徐執中 Division of Hematology & Oncology
- 余紹銘 Division of Hematology & Oncology
- Jen-Shi Chen Division of Hematology & Oncology
- Yung-Chang Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Ta-Chih Liu Division of Hematology & Oncology
- 吳敬炫 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
75 participants
-
Global
150 participants
